PL1845966T3 - Farmaceutyczny preparat do zastosowania w leczeniu lub profilaktyce chorób nowotworowych - Google Patents

Farmaceutyczny preparat do zastosowania w leczeniu lub profilaktyce chorób nowotworowych

Info

Publication number
PL1845966T3
PL1845966T3 PL06700207T PL06700207T PL1845966T3 PL 1845966 T3 PL1845966 T3 PL 1845966T3 PL 06700207 T PL06700207 T PL 06700207T PL 06700207 T PL06700207 T PL 06700207T PL 1845966 T3 PL1845966 T3 PL 1845966T3
Authority
PL
Poland
Prior art keywords
prophylaxis
treatment
glutamine
pharmaceutical preparation
alpha
Prior art date
Application number
PL06700207T
Other languages
English (en)
Inventor
Stephan Pyerzynowski
Martyna Kandefer-Szerszeń
Wojciech Rzeski
Original Assignee
Sgp & Sons Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgp & Sons Ab filed Critical Sgp & Sons Ab
Publication of PL1845966T3 publication Critical patent/PL1845966T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL06700207T 2005-01-11 2006-01-10 Farmaceutyczny preparat do zastosowania w leczeniu lub profilaktyce chorób nowotworowych PL1845966T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL372183A PL372183A1 (pl) 2005-01-11 2005-01-11 Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego
EP06700207A EP1845966B1 (en) 2005-01-11 2006-01-10 Pharmaceutical preparation for use in the treatment or prophylaxis of neoplastic diseases
PCT/PL2006/000003 WO2006075924A1 (en) 2005-01-11 2006-01-10 Antineoplastic preparation and the use of antineoplastic preparation

Publications (1)

Publication Number Publication Date
PL1845966T3 true PL1845966T3 (pl) 2011-02-28

Family

ID=36168380

Family Applications (2)

Application Number Title Priority Date Filing Date
PL372183A PL372183A1 (pl) 2005-01-11 2005-01-11 Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego
PL06700207T PL1845966T3 (pl) 2005-01-11 2006-01-10 Farmaceutyczny preparat do zastosowania w leczeniu lub profilaktyce chorób nowotworowych

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL372183A PL372183A1 (pl) 2005-01-11 2005-01-11 Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego

Country Status (12)

Country Link
US (1) US7759396B2 (pl)
EP (1) EP1845966B1 (pl)
JP (2) JP2008526838A (pl)
CN (1) CN101111241B (pl)
AT (1) ATE474570T1 (pl)
AU (1) AU2006205279B2 (pl)
CA (1) CA2593780C (pl)
DE (1) DE602006015608D1 (pl)
DK (1) DK1845966T3 (pl)
ES (1) ES2349233T3 (pl)
PL (2) PL372183A1 (pl)
WO (1) WO2006075924A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2033623A1 (en) * 2007-09-07 2009-03-11 Cutech S.R.L. Compositions comprising ornithine ketoglutarate (OKG)
WO2015123229A1 (en) * 2014-02-12 2015-08-20 The Regents Of The University Of California Compositions and methods for treating aging and age-related diseases and symptoms

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT393221B (de) * 1988-02-03 1991-09-10 Leopold Pharma Gmbh Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken
FR2775901B1 (fr) * 1998-03-13 2000-07-21 Logeais Labor Jacques Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments
SE0201713D0 (sv) * 2001-11-23 2002-06-06 Gramineer Internat Ab New methods and use III
WO2004012662A2 (en) * 2002-08-01 2004-02-12 Aesgen, Inc. Improved treatment of cancer with glutamine
AT412447B (de) * 2002-11-27 2005-03-25 C Y L Handelsges M B H Mittel mit zerstörender wirkung auf maligne tumore sowie verfahren zu seiner herstellung
EP2266585B1 (en) * 2003-05-07 2013-06-26 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
US20050124684A1 (en) * 2003-08-29 2005-06-09 Ying Du 5-(hydroxymethyl) furfural and derivatives as inhibitors of TNFalpha and IL-1beta production
ES2510690T3 (es) * 2004-12-17 2014-10-21 Alan B. Cash Método para extender la esperanza de vida y retrasar la aparición de enfermedad relacionada con la edad

Also Published As

Publication number Publication date
CA2593780C (en) 2013-11-26
CN101111241A (zh) 2008-01-23
EP1845966B1 (en) 2010-07-21
JP2013035864A (ja) 2013-02-21
WO2006075924A1 (en) 2006-07-20
ATE474570T1 (de) 2010-08-15
CA2593780A1 (en) 2006-07-20
EP1845966A1 (en) 2007-10-24
ES2349233T3 (es) 2010-12-29
JP2008526838A (ja) 2008-07-24
AU2006205279B2 (en) 2011-05-26
US7759396B2 (en) 2010-07-20
AU2006205279A1 (en) 2006-07-20
PL372183A1 (pl) 2006-07-24
US20080058422A1 (en) 2008-03-06
CN101111241B (zh) 2010-12-01
DE602006015608D1 (de) 2010-09-02
DK1845966T3 (da) 2010-11-08

Similar Documents

Publication Publication Date Title
TNSN07452A1 (en) Stabile active ingredient complex of salts of the o-acetylsalicylic acid with basic amino acids and glycine
MX341883B (es) Composicion farmaceutica para el tratamiento y prevencion de canceres.
ZA200707508B (en) 2-[isoquinolin-3-carbonyl) amino] -propionic acid derivatives as inhibitors of factors XI and IX for the treatment of thrombosis
TW200634051A (en) Processes for preparing a polypeptide
WO2011107653A8 (en) Use of levodopa, carbidopa and entacapone for treating parkinson's disease
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
WO2006128058A3 (en) Thyromimetics for the treatment of fatty liver diseases
NZ597260A (en) Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone
WO2007000001A3 (en) Pleuromutilin salts with salicylic acid, azelaic acid, sebacic acid and diclofenac
NZ608502A (en) Polypeptides that bind to human complement component c5
YU2003A (sh) Stabilne soli o-acetilsalicilne kiseline sa baznim amino-kiselinama
MX362164B (es) Tratamiento de enfermedad de articulacion degenerativa.
MX2009006865A (es) Proceso para la preparacion de compuestos 6,6-dimetil-3-aza-bicicl o-[3.1.0]-hexano utilizando intermediario bisulfitico.
TW200612922A (en) Inhibitors of hsp90
WO2007027476A3 (en) Treating premature ejaculation using gabapentin and pregabalin prodrugs
MX2008014273A (es) Procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion.
WO2006110724A3 (en) Method of treating schizophrenia prodrome
UA83900C2 (en) Amorphous forms of risedronate monosodium
PL1845966T3 (pl) Farmaceutyczny preparat do zastosowania w leczeniu lub profilaktyce chorób nowotworowych
MX2007007273A (es) Procedimiento de fabricacion de salicilamidas n-sustituidas.
JP2009515953A5 (pl)
HK1109029A1 (en) Nutritional and/or pharmaceutical preparation for use in prophylaxis and treatment of disturbances in microelements absorption from the alimentary canal
AU2003292006A1 (en) 3,5,3'-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof
TNSN07229A1 (en) Manufacture process of n-substituted salicylamides
RS20060210A (en) Amino acids with affinity for the alpha2delta-protein